Diltiazem Malate

Sold as Tiamate. Every FDA application for this active ingredient.

As of Nov 15, 2026, FDA lists 1 application for Diltiazem Malate (sold as Tiamate), first approved Oct 4, 1996, with 0 new uses approved and 0 published complete response letters.

First approved: Oct 4, 1996
Applications: 1
New uses approved: 0
Complete response letters: 0

What Pharmacies Pay

Median price per unit across package codes in CMS's weekly NADAC survey, Nov 11, 2026, before rebates; see every drug's price change

DILTIAZEM 120 MG TABLET: $0.091 per unitGeneric · -12% in a year
DILTIAZEM 12HR ER 120 MG CAP: $1.94 per unitGeneric · -12% in a year
DILTIAZEM 12HR ER 60 MG CAP: $1.34 per unitGeneric · -1% in a year
DILTIAZEM 12HR ER 90 MG CAP: $1.75 per unitGeneric · 0% in a year
DILTIAZEM 24H ER(CD) 120 MG CP: $0.146 per unitGeneric · -2% in a year
DILTIAZEM 24H ER(CD) 180 MG CP: $0.186 per unitGeneric · +4% in a year
DILTIAZEM 24H ER(CD) 240 MG CP: $0.205 per unitGeneric · -4% in a year
DILTIAZEM 24H ER(CD) 300 MG CP: $0.304 per unitGeneric · +3% in a year
DILTIAZEM 24H ER(CD) 360 MG CP: $0.315 per unitGeneric · -4% in a year
DILTIAZEM 24H ER(LA) 120 MG TB: $1.01 per unitGeneric · -36% in a year
DILTIAZEM 24H ER(LA) 180 MG TB: $1.17 per unitGeneric · -25% in a year
DILTIAZEM 24H ER(LA) 240 MG TB: $1.05 per unitGeneric · -25% in a year

Clinical Trials

12 open or ongoing studies name this ingredient as an intervention, including as a comparator; newest first. See all


A Comparison of Beta-blockers and Calcium Channel Blockers in Atrial FibrillationAtrial Fibrillation (AF) · University Hospital, Basel, Switzerland	Phase 4	Not yet recruiting	Oct 29, 2026
Vasodilator Therapy With Isosorbide Mononitrate or Diltiazem to Reduce Vasotoxicity in Patients With Gastrointestinal Cancer Receiving Fluoropyrimidine TherapyMalignant Digestive System Neoplasm · Mayo Clinic	Phase 1 / Phase 2	Recruiting	Mar 9, 2026
Catheter Ablation Versus Anti-arrhythmic Drugs for Premature Ventricular ComplexesPremature Ventricular Complexes, Premature Ventricular Contraction (PVC) · Western Sydney Local Health District	Not applicable	Recruiting	Mar 3, 2026
Flecainide Safety in Patients With Coronary Artery Disease and Atrial FibrillationAtrial Fibrillation (AF), Coronary Artery Disease · Universitaire Ziekenhuizen KU Leuven	Phase 4	Recruiting	Feb 12, 2026
Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With Post-Stroke Pneumonia: A Real-World Retrospective Cohort StudyPost-stroke Pneumonia · First Teaching Hospital of Tianjin University of Traditional Chinese Medicine	—	Not yet recruiting	Dec 4, 2025
The Therapeutic Value of Mavacamten in Hypertrophic Cardiomyopathy With Mid-to-Apical Left Ventricular ObstructionHypertrophic Cardiomyopathy (HCM) · Second Affiliated Hospital, Zhejiang University, School of Medicine	Phase 4	Enrolling by invitation	Aug 5, 2025
PERceptions of Diltiazem Versus ADEnosine for Treatment of Supraventricular Tachycardia in the Emergency DepartmentSupraventricular Tachycardia (SVT) · University of Iowa	—	Recruiting	Jul 25, 2025
Adenosine vs Diltiazem for Treatment of SVT in the EDSupraventricular Tachycardia (SVT) · Anne E. Zepeski	Phase 4	Recruiting	May 28, 2025

Applications

NDAs, BLAs and generic ANDAs for this ingredient, oldest first; each opens its full history

Approved	Application	Sponsor	Supplements	Marketing
Oct 4, 1996	TiamateNDA 20506 · New active ingredient	Merck	0	Discontinued

Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA